These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11780146)

  • 41. Design and synthesis of thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false positives to ATP-noncompetitive inhibitors.
    Radi M; Crespan E; Falchi F; Bernardo V; Zanoli S; Manetti F; Schenone S; Maga G; Botta M
    ChemMedChem; 2010 Aug; 5(8):1226-31. PubMed ID: 20509136
    [No Abstract]   [Full Text] [Related]  

  • 42. Structure-based design of flavone-based inhibitors of wild-type and T315I mutant of ABL.
    Choe H; Kim J; Hong S
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4324-7. PubMed ID: 23790540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain.
    Maru Y; Afar DE; Witte ON; Shibuya M
    J Biol Chem; 1996 Jun; 271(26):15353-7. PubMed ID: 8663064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crystal structure of a bifunctional transformylase and cyclohydrolase enzyme in purine biosynthesis.
    Greasley SE; Horton P; Ramcharan J; Beardsley GP; Benkovic SJ; Wilson IA
    Nat Struct Biol; 2001 May; 8(5):402-6. PubMed ID: 11323713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure. An anthropomorphic integrin.
    Humphries MJ; Mould AP
    Science; 2001 Oct; 294(5541):316-7. PubMed ID: 11598288
    [No Abstract]   [Full Text] [Related]  

  • 46. Dimerization of the human papillomavirus E7 oncoprotein in vivo.
    Clemens KE; Brent R; Gyuris J; Münger K
    Virology; 1995 Dec; 214(1):289-93. PubMed ID: 8525630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.
    Reckel S; Gehin C; Tardivon D; Georgeon S; Kükenshöner T; Löhr F; Koide A; Buchner L; Panjkovich A; Reynaud A; Pinho S; Gerig B; Svergun D; Pojer F; Güntert P; Dötsch V; Koide S; Gavin AC; Hantschel O
    Nat Commun; 2017 Dec; 8(1):2101. PubMed ID: 29235475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML.
    Lima MCP; Hornsby BD; Lim CS; Cheatham TE
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Yeast two-hybrid screening of cyclic peptide libraries using a combination of random and PI-deconvolution pooling strategies.
    Barreto K; Aparicio A; Bharathikumar VM; DeCoteau JF; Geyer CR
    Protein Eng Des Sel; 2012 Sep; 25(9):453-64. PubMed ID: 22763264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphotyrosine mapping in Bcr/Abl oncoprotein using phosphotyrosine-specific immonium ion scanning.
    Steen H; Fernandez M; Ghaffari S; Pandey A; Mann M
    Mol Cell Proteomics; 2003 Mar; 2(3):138-45. PubMed ID: 12644574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis.
    Demehri S; O'Hare T; Eide CA; Smith CA; Tyner JW; Druker BJ; Deininger MW
    Leukemia; 2010 Jan; 24(1):226-9. PubMed ID: 19759561
    [No Abstract]   [Full Text] [Related]  

  • 52. NMR Assignment Reveals an alpha-Helical Fold for the F-Actin Binding Domain of Human Bcr-Abl/c-Abl.
    Wiesner S; Hantschel O; Mackereth CD; Superti-Furga G; Sattler M
    J Biomol NMR; 2005 Aug; 32(4):335. PubMed ID: 16211486
    [No Abstract]   [Full Text] [Related]  

  • 53. Cell biology. Integrin crystal structure solved.
    Couzin J
    Science; 2001 Sep; 293(5536):1743-6. PubMed ID: 11546844
    [No Abstract]   [Full Text] [Related]  

  • 54. The other Achilles' heel of BCR-ABL1.
    De Keersmaecker K
    Haematologica; 2012 Jan; 97(1):2. PubMed ID: 22210326
    [No Abstract]   [Full Text] [Related]  

  • 55. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation.
    Müller R; Gräwert MA; Kern T; Madl T; Peschek J; Sattler M; Groll M; Buchner J
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10183-8. PubMed ID: 23733956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haematological cancer: BCL-ABL1 resistance mutation--breakthrough with axitinib.
    Killock D
    Nat Rev Clin Oncol; 2015 May; 12(5):252. PubMed ID: 25754950
    [No Abstract]   [Full Text] [Related]  

  • 57. De novo design by pharmacophore-based searches in fragment spaces.
    Lippert T; Schulz-Gasch T; Roche O; Guba W; Rarey M
    J Comput Aided Mol Des; 2011 Oct; 25(10):931-45. PubMed ID: 21922280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl.
    Schmidt N; Abendroth F; Vázquez O; Hantschel O
    RSC Chem Biol; 2022 Aug; 3(8):1008-1012. PubMed ID: 35975004
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correction to "improved coiled-coil design enhances interaction with bcr-abl and induces apoptosis".
    Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
    Mol Pharm; 2012 May; 9(5):1535. PubMed ID: 22444272
    [No Abstract]   [Full Text] [Related]  

  • 60. Controlling oligomerization of pharmaceutical proteins.
    Schein CH
    Pharm Acta Helv; 1994 Dec; 69(3):119-26. PubMed ID: 7846082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.